SCHEMBL14980361

SCHEMBL14980361

CN1CCC(N(C)C(=O)C(F)(F)F)CC1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.41
HTR2A P28223 4/20 0.41
HTR2C P28335 3/20 0.41
LMNA P02545 2/20 0.40
BRD4 O60885 1/20 0.39
TAF1 P21675 1/20 0.39
CECR2 Q9BXF3 1/20 0.39
KDM4E B2RXH2 1/20 0.38
KMT2A Q03164 1/20 0.38
HTR6 P50406 2/20 0.38
POLB P06746 1/20 0.37
CHRM2 P08172 1/20 0.37
CHRM4 P08173 1/20 0.37
CHRM5 P08912 1/20 0.37
CHRM1 P11229 1/20 0.37
CHRM3 P20309 1/20 0.37
MCHR1 Q99705 2/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19384067 0.84 CHRM2 (0.36) ALDH1A1POLBCHRM2CHRM4CHRM5
SCHEMBL14008935 0.83 ALDH1A1 (0.42) ALDH1A1HTR2AHTR2CLMNABRD4
SCHEMBL16219518 0.82 PDK2 (0.36) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL18469923 0.81 HTR2A (0.41) ALDH1A1HTR2AHTR2CLMNAKDM4E
SCHEMBL24368118 0.81 BRD4 (0.42) ALDH1A1BRD4TAF1CECR2KMT2A
SCHEMBL14720161 0.80 RAB9A (0.41) ALDH1A1POLBCHRM2CHRM4CHRM5
SCHEMBL12234268 0.79 FAAH (0.44) ALDH1A1KMT2APOLBCHRM2CHRM4
SCHEMBL18469925 0.77 PKM (0.37) HTR2AHTR2C
SCHEMBL14155193 0.77 ALDH1A1 (0.42) ALDH1A1HTR2AHTR2CLMNABRD4
SCHEMBL14995273 0.77 PDK2 (0.33) CHRM2CHRM4CHRM5CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9790499-B2 Functionally-modified oligonucleotides and subunits thereof SAREPTA THERAPEUTICS, INC. (US) 2017-10-17 US disclosed
US-9278987-B2 Functionally-modified oligonucleotides and subunits thereof SAREPTA THERAPEUTICS, INC. (US) 2016-03-08 US disclosed
US-20140330006-A1 FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF SAREPTA THERAPEUTICS, INC. (US) 2014-11-06 US disclosed
WO-2013074834-A1 FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF SAREPTA THERAPEUTICS, INC. (US) 2013-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140330006-A1 FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF RTCB, NSUN3, NSUN2 ALDH1A1 3163/4885HTR2A 4762/4885HTR2C 4810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.